Compounds and methods for treating diabetic vascular diseases
Compositions and methods of use of compounds of the formula and pharmaceutically acceptable salts thereof for the treatment of diabetic vascular diseases such as diabetic neuropathy, nephropathy, and retinopathy are described, wherein the substituents of the compound are further defined within the application.
1 . A method for treating diabetic vascular disease, diabetic neuropathy, nephropathy, or retinopathy in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
Y is a bond or
R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, hydroxy, alkyl, aryl, heteroaryl, alkaryl, and arylalkyl, wherein all nonhydrogen and hydroxy substituents may optionally be substituted from one or more of the group selected from alkyl, halogen, nitro, amino, haloalkyl, alkylamino, dialkylamino, acyl, and acyloxy;
Z is selected from the group consisting of alkyl, alkenyl, alkynyl, hydroxyl alkyl, aryl, heteroaryl, alkaryl, arylalkyl, heteroarylalkyl, alkoxy alkyl, alkylamino alkyl, carboxy alkyl, dialkylamino alkyl, amino alkyl, heterocycle, heterocycl alkyl, R 7 NH, R 7 R 7 N, carboxy, carbohydrate group, carbohydrate lactone group, and an alditol group wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group selected from the group selected from hydroxy, alkyl, alkoxy, halo, nitro, amino, cyano, alkylamino, dialkylamino, acyl, acyloxy, COOH, COOR 7 , OC(O)R 7 , CH(OH)R 7 , NHR 7 , NR 7 R 7 , C(O)NH 2 , C(O)NHR 7 , CONR 7 R 7 , NHC(O)O—R 7 , OSO 3 H, SO 3 H, SO 2 NHR7, SO 2 NR 7 R 7 , P(O)(OH)OR 7 , PO 2 H 2 P(O)(OH)R 7 , P(O)(OR 7 ) 2 , P(O)R 7 (OR 7 ), OPO 3 H, PO 3 H 2 , hydroxymethyl, and cyclic phosphate, wherein when possible, all may be optionally substituted by one or more R 6 ;
R 6 is independently selected from the group consisting of hydroxy, alkyl, alkoxy, acyloxy, halo, nitro, amino, cyano, halo alkyl, alkylamino, di alkylamino, acyl, and acyloxy;
R 7 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl alkyl, aryl, carboxy alkyl, alkylcarboxy alkyl, alkylcarboxy aryl, heterocycle, heterocycl alkyl, and heteroaryl, wherein all may be optionally substituted by one or more R 8 ; and
R 8 is independently selected from the group consisting of hydroxy, alkyl, alkoxy, acyloxy, halo, nitro, amino, cyano, and carboxy;
wherein two R 7 groups may come together to form a 4 to 7 membered ring.
2 . A method for treating diabetic vascular disease in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
Y is a bond or
R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, hydroxy, C 1-10 alkyl, aryl, heteroaryl, C 1-10 alkaryl, and aryl C 1-10 alkyl, wherein all nonhydrogen and hydroxy substituents may optionally be substituted from one or more of the group selected from C 1-10 alkyl, halogen, nitro, amino, haloC 1-10 alkyl, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, and acyloxy;
Z is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxyl C 1-10 alkyl, aryl, heteroaryl, C 1-10 alkaryl, aryl C 1-10 alkyl, heteroaryl C 1-10 alkyl, C 1-10 alkoxy C 1-10 alkyl, C 1-10 alkylamino C 1-10 alkyl, carboxy C 1-10 alkyl, C 1-10 dialkylamino C 1-10 alkyl, amino C 1-10 alkyl, heterocycle, heterocycl C 1-10 alkyl, R 7 NH, R 7 R 7 N, carboxy, carbohydrate group, carbohydrate lactone group, and an alditol group wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group selected from the group selected from hydroxy, C 1-10 alkyl, C 1-10 alkoxy, halo, nitro, amino, cyano, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, acyloxy, COOH, COOR 7 , OC(O)R 7 , CH(OH)R 7 , NHR 7 , NR 7 R 7 , C(O)NH 2 , C(O)NHR 7 , CONR 7 R 7 , NHC(O)O—R 7 , OSO 3 H, SO 3 H, SO 2 NHR7, SO 2 NR 7 R 7 , P(O)(OH)OR 7 , PO 2 H 2 P(O)(OH)R 7 , P(O)(OR 7 ) 2 , P(O)R 7 (OR 7 ), OPO 3 H, PO 3 H 2 , hydroxymethyl, and cyclic phosphate, wherein when possible, all may be optionally substituted by one or more R 6 ;
R 6 is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, haloC 1-10 alkyl, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, and acyloxy;
R 7 is independently selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkoxy, C 1-10 alkoxycarbonyl C 1-10 alkyl, aryl, carboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 aryl, heterocycle, heterocycl C 1-10 alkyl, and heteroaryl, wherein all may be optionally substituted by one or more R 8 ; and
R 8 is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, and carboxy;
wherein two R 7 groups may come together to form a 4 to 7 membered ring.
3 . A method for treating diabetic neuropathy, nephropathy, or retinopathy in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula I
or a pharmaceutically acceptable salt thereof, wherein:
Y is a bond or
R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, hydroxy, C 1-10 alkyl, aryl, heteroaryl, C 1-10 alkaryl, and aryl C 1-10 alkyl, wherein all nonhydrogen and hydroxy substituents may optionally be substituted from one or more of the group selected from C 1-10 alkyl, halogen, nitro, amino, haloC 1-10 alkyl, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, and acyloxy;
Z is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxyl C 1-10 alkyl, aryl, heteroaryl, C 1-10 alkaryl, aryl C 1-10 alkyl, heteroaryl C 1-10 alkyl, C 1-10 alkoxy C 1-10 alkyl, C 1-10 alkylamino C 1-10 alkyl, carboxy C 1-10 alkyl, C 1-10 dialkylamino C 1-10 alkyl, amino C 1-10 alkyl, heterocycle, heterocycl C 1-10 alkyl, R 7 NH, R 7 R 7 N, carboxy, carbohydrate group, carbohydrate lactone group, and an alditol group wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group selected from the group selected from hydroxy, C 1-10 alkyl, C 1-10 alkoxy, halo, nitro, amino, cyano, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, acyloxy, COOH, COOR 7 , OC(O)R 7 , CH(OH)R 7 , NHR 7 , NR 7 R 7 , C(O)NH 2 , C(O)NHR 7 , CONR 7 R 7 , NHC(O)O—R 7 , OSO 3 H, SO 3 H, SO 2 NHR7, SO 2 NR 7 R 7 , P(O)(OH)OR 7 , PO 2 H 2 P(O)(OH)R 7 , P(O)(OR 7 ) 2 , P(O)R 7 (OR 7 ), OPO 3 H, PO 3 H 2 , hydroxymethyl, and cyclic phosphate, wherein when possible, all may be optionally substituted by one or more R 6 ;
R 6 is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, haloC 1-10 alkyl, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, and acyloxy;
R 7 is independently selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkoxy, C 1-10 alkoxycarbonyl C 1-10 alkyl, aryl, carboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 aryl, heterocycle, heterocycl C 1-10 alkyl, and heteroaryl, wherein all may be optionally substituted by one or more R 8 ; and
R 8 is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, and carboxy;
wherein two R 7 groups may come together to form a 4 to 7 membered ring.
4 . A method for treating diabetic vascular disease in a mammal, the method comprising administering to the mammal in need thereof an effective amount of a compound of Formula II
or a pharmaceutically acceptable salt thereof, wherein:
Y is a bond or
Z is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxyl C 1-10 alkyl, aryl, heteroaryl, C 1-10 alkaryl, aryl C 1-10 alkyl, heteroaryl C 1-10 alkyl, C 1-10 alkoxy C 1-10 alkyl, C 1-10 alkylamino C 1-10 alkyl, carboxy C 1-10 alkyl, C 1-10 dialkylamino C 1-10 alkyl, amino C 1-10 alkyl, heterocycle, heterocycl C 1-10 alkyl, R 7 NH, R 7 R 7 N, carboxy, carbohydrate group, carbohydrate lactone group, and an alditol group wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group selected from the group selected from hydroxy, C 1-10 alkyl, C 1-10 alkoxy, halo, nitro, amino, cyano, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, acyloxy, COOH, COOR 7 , OC(O)R 7 , CH(OH)R 7 , NHR 7 , NR 7 R 7 , C(O)NH 2 , C(O)NHR 7 , CONR 7 R 7 , NHC(O)O—R 7 , OSO 3 H, SO 3 H, SO 2 NHR7, SO 2 NR 7 R 7 , P(O)(OH)OR 7 , PO 2 H 2 P(O)(OH)R 7 , P(O)(OR 7 ) 2 , P(O)R 7 (OR 7 ), OPO 3 H, PO 3 H 2 , hydroxymethyl, and cyclic phosphate, wherein when possible, all may be optionally substituted by one or more R 6 ;
R 6 is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, haloC 1-10 alkyl, C 1-10 alkylamino, diC 1-10 alkylamino, acyl, and acyloxy;
R 7 is independently selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkoxy, C 1-10 alkoxycarbonyl C 1-10 alkyl, aryl, carboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 aryl, heterocycle, heterocycl C 1-10 alkyl, and heteroaryl, wherein all may be optionally substituted by one or more R 8 ; and
R is independently selected from the group consisting of hydroxy, C 1-10 alkyl, C 1-10 alkoxy, acyloxy, halo, nitro, amino, cyano, and carboxy;
wherein two R 7 groups may come together to form a 4 to 7 membered ring.
5 . The method of claim 4 , wherein Y is a bond or C
Z is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxyl C 1-10 alkyl, aryl, and heteroaryl, wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group consisting of hydroxyl, COOH, COOR 7 , OC(O)R 7 , CH(OH)R 7 , NHR 7 , NR 7 R 7 , C(O)NH 2 , C(O)NHR 7 , CONR 7 R 7 , NHC(O)O—R 7 ; and
R 7 is independently selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkoxy, C 1-10 alkoxycarbonyl C 1-10 alkyl, aryl, carboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 alkyl, C 1-10 alkylcarboxy C 1-10 aryl, heterocycle, heterocycl C 1-10 alkyl, and heteroaryl;
wherein two R 7 groups may come together to form a 4 to 7 membered ring.
6 . The method of claim 4 , wherein
Y is a bond or
Z is selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, hydroxyl C 1-10 alkyl, and aryl, wherein all may optionally be substituted by one or more R 5 ;
R 5 is independently selected from the group consisting of hydroxyl, COOH, COOR 7 , OC(O)R 7 ; and
R 7 is independently selected from the group consisting of C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, and C 1-10 alkoxy.
7 . The method of claim 4 , wherein the compound or its pharmaceutically acceptable salt are selected from the group consisting of
8 . The method of claim 7 , wherein the compound or its pharmaceutically acceptable salt is
9 . The method of claim 4 , wherein the compound or its pharmaceutically acceptable salt are administered through a conjunctival administration, nasal administration, a buccal administration, an epidermal administration, or a parenteral administration.
10 . The method of claim 4 , wherein the compound or its pharmaceutically acceptable salt are administered orally.
11 . The method of treating diabetic vascular disease according to claim 4 , wherein the compound or its pharmaceutically acceptable salt are administered through a conjunctival administration.
12 . The method of treating diabetic vascular disease according to claim 11 , wherein the compound or its pharmaceutically acceptable salt is administered through the conjunctival administration in a form of an ophthalmic solution, an ophthalmic suspension, an ophthalmic gel, an ophthalmic ointment, or an ophthalmic strip or insert.
13 . The method of claim 4 , wherein the administration is in an amount of from about 0.01 mg/kg/day to about 1000 mg/kg/day.
14 . The method of claim 4 , wherein the therapeutically effective amount is in the form of a pharmaceutical formulation comprising the compound and a suitable carrier or excipient thereof.
15 . A method for the treatment of a human afflicted with a diabetic vascular disease, the method comprising administering to the human in need of such a treatment a therapeutically effective amount of a composition comprising a compound represented by the formula:
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.